These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32797088)

  • 21. Estimation of number of subjects required for comparison of drug versus control in adaptive designs.
    Hu FF; Hu JH
    Ann Acad Med Singap; 2000 Sep; 29(5):565-9. PubMed ID: 11126689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Precision Trial Drawer, a Computational Tool to Assist Planning of Genomics-Driven Trials in Oncology.
    Melloni GEM; Guida A; Curigliano G; Botteri E; Esposito A; Kamal M; Le Tourneau C; Riva L; Magi A; de Maria R; Pelicci P; Mazzarella L
    JCO Precis Oncol; 2018 Nov; 2():1-16. PubMed ID: 35135136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and analysis of umbrella trials: Where do we stand?
    Ouma LO; Wason JMS; Zheng H; Wilson N; Grayling M
    Front Med (Lausanne); 2022; 9():1037439. PubMed ID: 36313987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach.
    Aromataris E; Fernandez R; Godfrey CM; Holly C; Khalil H; Tungpunkom P
    Int J Evid Based Healthc; 2015 Sep; 13(3):132-40. PubMed ID: 26360830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bias in retrospective analyses of biomarker effect using data from an outcome-adaptive randomized trial.
    Ji L; McShane LM; Krailo M; Sposto R
    Clin Trials; 2019 Dec; 16(6):599-609. PubMed ID: 31581815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
    Wang X; Zhou J; Wang T; George SL
    J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generalized multidimensional dynamic allocation method.
    Lebowitsch J; Ge Y; Young B; Hu F
    Stat Med; 2012 Dec; 31(28):3537-44. PubMed ID: 22736449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A group sequential, response-adaptive design for randomized clinical trials.
    Karrison TG; Huo D; Chappell R
    Control Clin Trials; 2003 Oct; 24(5):506-22. PubMed ID: 14500050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mass weighted urn design--A new randomization algorithm for unequal allocations.
    Zhao W
    Contemp Clin Trials; 2015 Jul; 43():209-16. PubMed ID: 26091947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. More ethical and more efficient clinical research: multiplex trial design.
    Keus F; van der Horst IC; Nijsten MW
    BMC Res Notes; 2014 Aug; 7():530. PubMed ID: 25125365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statistical considerations of phase 3 umbrella trials allowing adding one treatment arm mid-trial.
    Ren Y; Li X; Chen C
    Contemp Clin Trials; 2021 Oct; 109():106538. PubMed ID: 34384890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
    Wick W; Dettmer S; Berberich A; Kessler T; Karapanagiotou-Schenkel I; Wick A; Winkler F; Pfaff E; Brors B; Debus J; Unterberg A; Bendszus M; Herold-Mende C; Eisenmenger A; von Deimling A; Jones DTW; Pfister SM; Sahm F; Platten M
    Neuro Oncol; 2019 Jan; 21(1):95-105. PubMed ID: 30277538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A simulation study of the validity and efficiency of design-adaptive allocation to two groups in the regression situation.
    Aickin M
    Int J Biostat; 2009 May; 5(1):Article 19. PubMed ID: 20224630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lay public's understanding of equipoise and randomisation in randomised controlled trials.
    Robinson EJ; Kerr CE; Stevens AJ; Lilford RJ; Braunholtz DA; Edwards SJ; Beck SR; Rowley MG
    Health Technol Assess; 2005 Mar; 9(8):1-192, iii-iv. PubMed ID: 15763039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations.
    Hu C; Dignam JJ
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32923854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical trial designs incorporating predictive biomarkers.
    Renfro LA; Mallick H; An MW; Sargent DJ; Mandrekar SJ
    Cancer Treat Rev; 2016 Feb; 43():74-82. PubMed ID: 26827695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statistical comparison of random allocation methods in cancer clinical trials.
    Hagino A; Hamada C; Yoshimura I; Ohashi Y; Sakamoto J; Nakazato H
    Control Clin Trials; 2004 Dec; 25(6):572-84. PubMed ID: 15588744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exact group-sequential designs for clinical trials with randomized play-the-winner allocation.
    Stallard N; Rosenberger WF
    Stat Med; 2002 Feb; 21(4):467-80. PubMed ID: 11836730
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.